Observational studyJournal of the peripheral nervous system : JPNS2025
Prognostic Nutritional Index as a Biomarker of Disease Severity and Long-Term Outcome in Guillain-Barré Syndrome.
Observational study in Journal of the peripheral nervous system : JPNS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
aimsGuillain-Barré syndrome (GBS) exhibits clinical heterogeneity and variable progression. In low-resource settings, malnutrition and limited treatment worsen prognosis, underscoring the need for a simple prognostic tool. This study evaluated the Prognostic Nutritional Index (PNI) and Nutritional Risk Index (NRI) in relation to GBS severity and long-term outcomes, comparing their predictive value with standard prognostic indicators.
methodsAn observational cohort study of 252 GBS patients enrolled between 2019 and 2024 was conducted. PNI and NRI were calculated using serum albumin, lymphocyte count, and body weight. The GBS-disability score (GBS-DS) assessed baseline severity and 26-week outcomes. Statistical analysis included Chi-square tests, Mann-Whitney U tests, Spearman's ρ, and logistic regression to identify predictors. ROC analysis determined optimal PNI cut-offs, confirmed by Kaplan-Meier survival curves.
resultsPNI, unlike NRI, was significantly reduced in severe GBS (GBS-DS > 3) compared to mild/moderate GBS (GBS-DS ≤ 3). PNI correlated with GBS-DS (ρ = -0.62), MRC sum score (ρ = 0.5), hemoglobin (ρ = 0.53), and neutrophil count (ρ = -0.35) (all p < 0.0001). PNI independently predicted disease severity (odds ratio [OR] = 0.91; p = 0.036) and 26-week outcomes (OR = 0.93; p = 0.033). Area under the ROC curve (AUC) was 0.769 for severity and 0.719 for 26-week outcomes. PNI cut-offs of 49.395 and 45.72 predicted severe GBS and long-term poor outcome, respectively. Kaplan Meier analysis confirmed patients with PNI < 45.72 required a longer time to gain independent locomotion (p < 0.0001).
interpretationLower PNI, but not NRI, is associated with greater GBS severity and poor long-term outcomes. PNI independently predicted disease severity and 26-week outcomes, with specific cut-offs identifying patients requiring longer recovery, supporting its prognostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.